Nurix Therapeutics, Inc. NRIX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$264.46M-36.6% | -$193.57M-34.5% | -$143.95M+20.2% | -$180.36M-53.9% | ||
| $8.74M-6.2% | $9.32M+23.7% | $7.53M+39.2% | $5.41M+100% | ||
| $37.97M+11.9% | $33.93M+0.8% | $33.67M+19.7% | $28.13M+78.0% | ||
| -$249.47M-44.5% | -$172.58M— | —— | -$159.81M-89.4% | ||
| $14M+51.0% | $9.27M+10.4% | $8.4M-31.4% | $12.24M+116% | ||
| $147.85M+157% | -$257.71M— | —— | —— | ||
| $238.64M-50.9% | $485.67M+14,997% | $3.22M-97.3% | $117.33M-23.8% | ||
| $137.03M— | —— | —— | —— | ||
| -$263.47M-44.9% | -$181.86M— | —— | -$172.05M-91.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Nurix Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.